tradingkey.logo

Kepler upgrades Stratec to 'buy' on projected demand recovery

ReutersJun 25, 2025 8:55 AM

Kepler upgrades the German biomedical systems manufacturer Stratec SBSG.DE to "buy" from "hold", as it expects demand to recover

The broker points to a slump in demand since the Covid pandemic, during which the market for molecular diagnostics was saturated

The stock value has dropped 83 percent from its peak value in 2021, Kepler adds

However, the analyst says that "the business is clearly viable", "the recovery of industrial demand is a question of time" and "leverage is not a concern"

Therefore, Kepler views Stratec's stock as undervalued

Stratec shares are up 4.65%, making Stratec on of the top gainers on the .SDAXI index

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI